Home » Biovail, Pharma Pass II Ink Development Agreement
Biovail, Pharma Pass II Ink Development Agreement
Canadian drugmaker Biovail’s subsidiary, Biovail Laboratories International, has signed an agreement with Pharma Pass II for two early-stage development products — BVF-068, a product for the treatment of a central nervous system disorder, and BVF-247, a novel formulation of a cardiovascular agent.
Biovail has acquired the worldwide rights to develop, manufacture and market BVF-068 and BVF-247. In return, Biovail will pay an upfront fee and is obligated to make additional milestone payments for each product.
The agreement also stipulates the payment of tiered, single-digit royalties on net commercial sales of the product, Biovail said.
Upcoming Events
-
04Apr
-
11Apr
-
14Apr
-
25Apr
-
14May